What is Guangxi Wuzhou Zhongheng Group Co., Ltd's (600252.SS) StockRank?

MoatMap's StockRank for Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) is 29/100, with a Sell signal. This is a composite score combining Quality (39), Value (50), and Momentum (31) factor ranks across MoatMap's 20,000+ stock universe.

Does Guangxi Wuzhou Zhongheng Group Co., Ltd have an economic moat?

Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Guangxi Wuzhou Zhongheng Group Co., Ltd a buy, hold, or sell?

MoatMap's current signal for Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Guangxi Wuzhou Zhongheng Group Co., Ltd in?

Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600252.SS

SELLREMOVE

Guangxi Wuzhou Zhongheng Group Co., Ltd · Healthcare · China · $1.0B · Avg Vol: $11M/d

StockRank

P/E (TTM)

—

ROE

-7.7%

D/E

0.3x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Guangxi Wuzhou Zhongheng is a traditional Chinese medicine and generic pharma manufacturer. It lacks the high-end biologics capabilities or global regulatory moats required to benefit from our CDMO theme.

COMPANY DESCRIPTION

Guangxi Wuzhou Zhongheng Group Co., Ltd. develops and manufactures Traditional Chinese Medicine (TCM) injections, cardiovascular pharmaceuticals, and health products. The company's competitive moat is anchored by its flagship product, Xuesaitong Injection, which commands a leading market share in China's cardiovascular treatment segment. It is a prominent state-controlled TCM enterprise with a vertically integrated supply chain from herb cultivation to clinical distribution.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	401M	439M	311M	258M	-13.6%
EPS	0.00	0.00	-0.02	-0.02	6.5%
Shares	3.5B	3.5B	3.4B	3.2B	-8.4%
Debt	290M	264M	293M	261M	-3.4%
Equity	963M	971M	890M	794M	-6.3%
Op CF	-25M	60M	71M	-3M	18.5%
Inv CF	37M	-120M	140M	-10M	—
Fin CF	49M	-43M	-33M	-83M	—

PRICE (1M)-19.6%

SMA 50SMA 200

$0.29

RSI (14)

32.2

52W High

$0.48

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-5.9%37.9

ROE

-7.7%36.8

GP/Assets

7.0%21.4

Op. Margin

-4.1%32.4

FCF/Assets

1.8%56.9

Piotroski

—55.7

Int. Cover

-7.2x27.8

D/E Ratio

0.32x42.2

Current Ratio

2.13x39.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-57.0x94.5

P/FCF

260.8x32.6

P/B

1.2x73.2

P/S

4.1x46.4

Div Yield

—N/A

Momentum

52W High %

61%41.9

RS 6M

-42%27.8

SMA 50/200

0.90x33.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.0B

P/E (Forward)

—

Gross Margin

44.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600252.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600252.SS	Guangxi Wuzhou Zhongheng Group Co., Ltd(you)	$1.0B	29	SELL
688176.SS	Jiangsu Yahong Meditech Co., Ltd.	$961M	30	SELL
002038.SZ	Beijing SL Pharmaceutical Co., Ltd.	$893M	28	SELL
603567.SS	Heilongjiang ZBD Pharmaceutical Co., Ltd.	$994M	26	SELL
002940.SZ	Zhejiang AngLiKang Pharmaceutical CO.,LTD.	$1.0B	25	SELL
300702.SZ	Zhejiang Tianyu Pharmaceutical Co., Ltd.	$989M	26	SELL
300363.SZ	Porton Pharma Solutions Ltd.	$1.2B	26	SELL
600422.SS	KPC Pharmaceuticals,Inc.	$999M	24	SELL
688621.SS	Beijing Sun-Novo Pharmaceutical Research Co., Ltd.	$894M	26	SELL
300267.SZ	Hunan Er-Kang Pharmaceutical Co., Ltd	$1.1B	34	SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.1%

Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) — Stock Score Summary

Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) has a MoatMap StockRank of 29/100 based on Quality (39/100), Value (50/100), and Momentum (31/100) factor scores. The current signal is SELL. Guangxi Wuzhou Zhongheng is a traditional Chinese medicine and generic pharma manufacturer. It lacks the high-end biologics capabilities or global regulatory moats required to benefit from our CDMO theme.

Key Financial Metrics

Price	$0.29
Market Cap	$1.0B
Price/Book	1.24
Return on Equity	-7.7%
Return on Invested Capital	-5.9%
Debt/Equity	31.76
Gross Margin	44.4%
Operating Margin	-4.1%
Revenue Growth	-52.1%
Free Cash Flow	$4M

Guangxi Wuzhou Zhongheng Group Co., Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Guangxi Wuzhou Zhongheng Group Co., Ltd’s (600252.SS) StockRank?: MoatMap’s StockRank for Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) is 29/100, with a Sell signal. It is a composite of Quality (39), Value (50), and Momentum (31) factor ranks across MoatMap’s 20,000+ stock universe.
Does Guangxi Wuzhou Zhongheng Group Co., Ltd have an economic moat?: Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Guangxi Wuzhou Zhongheng Group Co., Ltd a buy, hold, or sell?: MoatMap’s current signal for Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Guangxi Wuzhou Zhongheng Group Co., Ltd in?: Guangxi Wuzhou Zhongheng Group Co., Ltd (600252.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).